Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study
Open Access
- 9 May 2013
- Vol. 3 (5), e002737
- https://doi.org/10.1136/bmjopen-2013-002737
Abstract
Objectives Children with Crohn's disease grow poorly, and inflammation depresses the response of insulin-like growth factor-1 (IGF-1) to growth hormone. Correcting the inflammation normalises growth velocity; however, removing inflammation cannot be achieved in all children. Our lack of understanding of IGF-1 kinetics has hampered its use, particularly as high IGF-1 concentrations over long periods may predispose to colon cancer. We hypothesised that mathematical modelling of IGF-1 would define dosing regimes that return IGF-1 concentrations into the normal range, without reaching values that risk cancer. Design Pharmacokinetic intervention study. Setting Tertiary paediatric gastroenterology unit. Participants 8 children (M:F; 4:4) entered the study. All completed: 5 South Asian British; 2 White British; 1 African British. Inclusion criteria: Children over 10 years with active Crohn's disease (C reactive protein >10 mg/l or erythrocyte sedimentation rate >25 mm/h) and height velocity <–2 SD score. Exclusion criteria: closed epiphyses; corticosteroids within 3 months; neoplasia or known hypersensitivity to recombinant human IGF-1 (rhIGF-1). Interventions Subcutaneous rhIGF-1 (120 μg/kg) per dose over two admissions: the first as a single dose and the second as twice daily doses over 5 days. Primary outcome Significant increase in circulating IGF-1. Secondary outcomes Incidence of side effects of IGF-1. A mathematical model of circulating IGF-1 (Ac) was developed to include parameters of endogenous synthesis (Ksyn); exogenous uptake (Ka) from the subcutaneous dose (As): and IGF-1 clearance: where dAc/dt=Ksyn − Kout×Ac+Ka×As. Results Subcutaneous IGF-1 increased concentrations, which were maintained on twice daily doses. In covariate analysis, disease activity reduced Ksyn (pConclusions By using age, weight and disease activity scaling in IGF-1 dosing, over 95% of children will have normalised IGF-1 concentrations below +2.5 SDs of the normal population mean, a level not associated with cancer risk.Keywords
This publication has 45 references indexed in Scilit:
- A Randomized Controlled Trial of Growth Hormone in Active Pediatric Crohn DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2010
- Growth Hormone Treatment for Growth Failure in Pediatric Patients with Crohn's DiseaseThe Journal of Pediatrics, 2008
- Interventions for growth failure in childhood Crohn's diseaseEmergencias, 2006
- Protein-Losing Enteropathy in Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2005
- Insulin-Like Growth Factor I and the Development of Colorectal Neoplasia in AcromegalyJournal of Clinical Endocrinology & Metabolism, 2000
- Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failureKidney International, 1996
- Pharmacokinetics of recombinant human insulin-like growth factor-1 in dialysis patientsKidney International, 1995
- Acceleration of linear growth following intestinal resection for Crohn diseaseEuropean Journal of Pediatrics, 1990
- Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease.Gut, 1983
- Bootstrap Methods: Another Look at the JackknifeThe Annals of Statistics, 1979